GT200800211A - Derivados de dihidropirazolopirimidinona - Google Patents

Derivados de dihidropirazolopirimidinona

Info

Publication number
GT200800211A
GT200800211A GT200800211A GT200800211A GT200800211A GT 200800211 A GT200800211 A GT 200800211A GT 200800211 A GT200800211 A GT 200800211A GT 200800211 A GT200800211 A GT 200800211A GT 200800211 A GT200800211 A GT 200800211A
Authority
GT
Guatemala
Prior art keywords
group
compounds
dihydropirazolopirimidinone
derivatives
renting
Prior art date
Application number
GT200800211A
Other languages
English (en)
Inventor
Sakamoto Toshihiro
Sunami Satoshi
Yamamoto Fuyuki
Niiyama Kenji
Bamba Makoto
Takahashi Keiji
Furuyama Hidetomo
Sagara Takeshi
Otsuki Sachie
Nishibata Toshihide
Yoshizumi Takashi
Hirai Hiroshi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200800211(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200800211A publication Critical patent/GT200800211A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA GENERAL (I) EN LA QUE A1 SE SELECCIONA DE LA FÓRMULA (AA1), R1 ES UN GRUPO ALQUENILO INFERIOR O UN GRUPO ALQUINILO INFERIOR, R2 ES UN GRUPO FENILO, PIRIDILO O TIENILO, R5 Y R6 SON UN ÁTOMO DE HIDRÓGENO, UN GRUPO ALQUILO INFERIOR O UN GRUPO HIDROXIALQUILO INFERIOR, ETC. LOS COMPUESTOS DE LA INVENCIÓN TIENEN EXCELENTE EFECTO INHIBIDOR DE QUINASA WEEL Y SON POR LO TANTO, ÚTILES EN EL CAMPO DE LAS MEDICINAS, ESPECIALMENTE EN EL TRATAMIENTO DE DIVERSOS CÁNCERES.
GT200800211A 2006-04-27 2008-10-10 Derivados de dihidropirazolopirimidinona GT200800211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27

Publications (1)

Publication Number Publication Date
GT200800211A true GT200800211A (es) 2009-04-07

Family

ID=38655640

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800211A GT200800211A (es) 2006-04-27 2008-10-10 Derivados de dihidropirazolopirimidinona

Country Status (39)

Country Link
US (4) US7935708B2 (es)
EP (2) EP2017278B1 (es)
JP (2) JP4513919B2 (es)
KR (1) KR101409161B1 (es)
CN (1) CN101432284B (es)
AR (1) AR060635A1 (es)
AT (1) ATE475662T1 (es)
AU (1) AU2007244185B2 (es)
BR (1) BRPI0710081A2 (es)
CA (1) CA2650119C (es)
CR (1) CR10359A (es)
CY (2) CY1111069T1 (es)
DE (1) DE602007008085D1 (es)
DK (2) DK2016080T3 (es)
DO (1) DOP2007000084A (es)
EC (1) ECSP088812A (es)
ES (2) ES2348751T3 (es)
GT (1) GT200800211A (es)
HK (1) HK1132498A1 (es)
HN (1) HN2008001532A (es)
HR (2) HRP20100563T1 (es)
HU (1) HUE032987T2 (es)
IL (1) IL194367A (es)
LT (1) LT2017278T (es)
MA (1) MA30428B1 (es)
MX (1) MX2008013063A (es)
MY (1) MY145408A (es)
NO (1) NO341617B1 (es)
NZ (1) NZ571196A (es)
PE (1) PE20080695A1 (es)
PL (2) PL2017278T3 (es)
PT (2) PT2017278T (es)
RU (1) RU2437885C2 (es)
SI (2) SI2017278T1 (es)
SV (1) SV2009003060A (es)
TW (1) TWI409262B (es)
UA (1) UA96152C2 (es)
WO (2) WO2007126122A1 (es)
ZA (1) ZA200807748B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
JPWO2009054332A1 (ja) * 2007-10-23 2011-03-03 萬有製薬株式会社 ピリドン置換ジヒドロピラゾロピリミジノン誘導体
ES2430053T3 (es) * 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
CA2745959A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
CA2750716A1 (en) * 2009-02-25 2010-09-02 Msd K.K. Pyrimidopyrimidoindazole derivative
US20120157342A1 (en) * 2009-09-02 2012-06-21 Shinji Mizuarai Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
CA2817968C (en) 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
KR102093947B1 (ko) * 2011-04-27 2020-03-26 제온 코포레이션 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN104011049A (zh) * 2011-10-20 2014-08-27 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
JP2015511245A (ja) * 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
AU2014251087B2 (en) 2013-04-09 2019-05-02 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
KR20170045751A (ko) * 2014-12-17 2017-04-27 데루타-후라이 화마 가부시키가이샤 고령이나 말기의 암환자를 치료 또는 경감하기 위한 의약 조성물
EP3294726A1 (en) 2015-04-17 2018-03-21 AbbVie Inc. Indazolones as modulators of tnf signaling
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Tnf信號傳遞之三環調節劑
UY36628A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
MY191938A (en) * 2015-09-01 2022-07-19 Taiho Pharmaceutical Co Ltd Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
US10947238B2 (en) * 2015-11-01 2021-03-16 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
CN106271589B (zh) * 2016-06-23 2018-12-28 中山市美捷时包装制品有限公司 一种用于预装阀杆、弹簧、垫片的组装设备
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
MX2019003026A (es) 2016-09-15 2019-07-01 Boehringer Ingelheim Int Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
EP3572413B1 (en) * 2017-01-23 2021-11-03 Shijiazhuang Sagacity New Drug Development Co., Ltd. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one derivative as wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
EP3604306B1 (en) 2017-03-23 2022-10-26 Shanghai de Novo Pharmatech Co., Ltd. Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
AU2018312448B2 (en) * 2017-08-01 2022-09-15 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
EP3712150B1 (en) 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019134539A1 (zh) * 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
EP3758706A4 (en) * 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
MX2020009372A (es) * 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
CN112955454A (zh) * 2018-10-26 2021-06-11 石家庄智康弘仁新药开发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
WO2020192581A1 (zh) 2019-03-22 2020-10-01 首药控股(北京)有限公司 Wee1抑制剂及其制备和用途
CA3136492A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
SG11202111315XA (en) 2019-04-30 2021-11-29 Shijiazhuang Sagacity New Drug Development Co Ltd Crystal form of wee1 inhibitor compound and use thereof
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
KR20220042127A (ko) * 2019-06-28 2022-04-04 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용
CN114599399A (zh) 2019-10-25 2022-06-07 阿斯利康(瑞典)有限公司 治疗癌症的方法
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US20230159540A1 (en) 2020-06-17 2023-05-25 Wigen Biomedicine Technology (shanghai) Co., Ltd. PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN116848117A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN116848118A (zh) * 2021-02-09 2023-10-03 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
WO2022232634A1 (en) 2021-04-29 2022-11-03 Novartis Ag Deubiquitinase-targeting chimeras and related methods
US20240182482A1 (en) 2021-04-30 2024-06-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused cyclic compound as wee-1 inhibitor, preparation method therefor and use thereof
AU2022280213A1 (en) 2021-05-28 2023-08-31 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Wee1 inhibitor and use thereof
WO2023041066A1 (zh) * 2021-09-18 2023-03-23 优领医药科技(香港)有限公司 含嘧啶并二氢吡唑啉酮类衍生物、其药学上可接受的盐及其制备方法和应用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
TW202322812A (zh) * 2021-11-01 2023-06-16 大陸商正大天晴藥業集團股份有限公司 吡唑[3,4-d]嘧啶-3-酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687A (zh) * 2022-01-18 2023-07-21 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184A (zh) * 2022-03-25 2023-10-03 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
WO2024012549A1 (zh) * 2022-07-15 2024-01-18 映恩生物制药(苏州)有限公司 一种嘧啶并五元杂环化合物、其制备方法和用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
DK0547165T3 (da) 1990-09-28 2000-03-27 Smithkline Beecham Corp Fremgangsmåde til fremstilling af vandopløselige camptothecinanaloger såvel som forbindelserne 10-hydroxy-11-C(1-6)-alkoxyc
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス.アー. 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス.アー. 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
WO2003091255A1 (en) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
AU2004212421B2 (en) * 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
MX2007000214A (es) 2004-07-01 2007-05-10 Asubio Pharma Co Ltd Derivado de tienopirazol que tiene actividad inhibidora de pde 7.
US7947695B2 (en) 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

Also Published As

Publication number Publication date
US20110189130A1 (en) 2011-08-04
CN101432284A (zh) 2009-05-13
KR101409161B1 (ko) 2014-06-19
EP2016080B1 (en) 2010-07-28
PE20080695A1 (es) 2008-06-28
EP2017278A1 (en) 2009-01-21
HK1132498A1 (en) 2010-02-26
HUE032987T2 (en) 2017-11-28
EP2017278B1 (en) 2016-11-02
DE602007008085D1 (en) 2010-09-09
JP2010132689A (ja) 2010-06-17
PL2016080T3 (pl) 2011-03-31
PL2017278T3 (pl) 2017-10-31
AU2007244185A1 (en) 2007-11-08
US8791125B2 (en) 2014-07-29
CR10359A (es) 2009-02-19
SV2009003060A (es) 2009-04-28
CA2650119A1 (en) 2007-11-08
NO20084968L (no) 2008-11-26
US20100063024A1 (en) 2010-03-11
WO2007126122A1 (en) 2007-11-08
MX2008013063A (es) 2008-12-16
ZA200807748B (en) 2009-10-28
ECSP088812A (es) 2008-11-27
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
JP4513919B2 (ja) 2010-07-28
HRP20161763T1 (hr) 2017-02-24
BRPI0710081A2 (pt) 2011-08-02
AU2007244185B2 (en) 2012-10-04
RU2437885C2 (ru) 2011-12-27
LT2017278T (lt) 2017-01-25
PT2017278T (pt) 2017-01-03
TWI409262B (zh) 2013-09-21
SI2016080T1 (sl) 2011-03-31
ES2348751T3 (es) 2010-12-13
CY1118526T1 (el) 2017-07-12
US20070254892A1 (en) 2007-11-01
KR20090017491A (ko) 2009-02-18
JPWO2007126128A1 (ja) 2009-09-17
US20140303178A1 (en) 2014-10-09
CY1111069T1 (el) 2012-05-23
DK2016080T3 (da) 2010-11-22
AR060635A1 (es) 2008-07-02
DOP2007000084A (es) 2007-12-31
US7935708B2 (en) 2011-05-03
ATE475662T1 (de) 2010-08-15
NO341617B1 (no) 2017-12-11
NZ571196A (en) 2011-03-31
UA96152C2 (en) 2011-10-10
IL194367A (en) 2014-12-31
PT2016080E (pt) 2010-10-14
US7834019B2 (en) 2010-11-16
WO2007126128A1 (ja) 2007-11-08
MY145408A (en) 2012-02-15
EP2016080A4 (en) 2009-05-13
ES2609087T3 (es) 2017-04-18
EP2017278A4 (en) 2009-04-22
TW200811176A (en) 2008-03-01
HN2008001532A (es) 2009-06-10
EP2016080A1 (en) 2009-01-21
CA2650119C (en) 2017-03-14
JP5167291B2 (ja) 2013-03-21
CN101432284B (zh) 2012-08-15
DK2017278T3 (en) 2017-02-13
IL194367A0 (en) 2009-08-03
HRP20100563T1 (hr) 2010-11-30
SI2017278T1 (sl) 2017-05-31

Similar Documents

Publication Publication Date Title
GT200800211A (es) Derivados de dihidropirazolopirimidinona
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MA34064B1 (fr) Compose heterocyclique
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
EA200970156A1 (ru) Пиридизиноновые производные
ATE540028T1 (de) Als hsp90-inhibitoren geeignete triazinon- und diazinonderivate
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
MA32508B1 (fr) Composes organiques
EA201170772A1 (ru) Органические соединения
CY1110108T1 (el) Παραγωγα ισοκινολινης ως αναστολεις της rho-κινασης
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
ECSP109958A (es) Derivados de pirimidina 934
ECSP109964A (es) Pirimidinas bicíclicas fusionadas
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
CO6341477A2 (es) Compuestos pirrolopirimidincarboxamida, procesos para su producción y composiciones farmaceúticas que comprenden dichos compuestos
CU20160010A7 (es) NUEVOS COMPUESTOS ISOINDOLlNA O ISOQUINOLlNA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS Bcl-2 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN